Parkinson's disease (PD) affects over 6 million individuals worldwide and is considered the second most common neurodegenerative disease, after Alzheimer's disease (Lyons and Pahwa 2011) . PD is an idiopathic disorder caused by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and subsequent depletion of dopamine levels in the striatum (Chen and others 2005) . Protection of the scant remaining dopaminergic neurons has been suggested as a therapeutic stratagem since the discovery of neuroprotective effects of glial cell line-derived neurotrophic factor (GDNF) on dopaminergic neurons in vitro (Lin and others 1993) . Following on these investigations, we have assessed the efficacy of the novel IDLVs for therapy in a PD rodent model. We report that IDLVs can provide efficient, long-lived and transcriptionally targeted transduction of brain cells when injected ahead of striatal lesioning.
While hGDNF gene expression was higher from IPLVs, transduction with IDLVs resulted in equally efficient neuroprotection and long-term improvements of behavioral symptoms in 6-OHDA-lesioned rats. Lack of significant IDLV integration was confirmed in animals injected with vector following striatal lesioning. These results underscore the effectiveness of IDLVs in the CNS and the scope for low-dose, low-risk therapies based on these novel vectors. 
Materials and Methods

Lentiviral vector production and titration
Animals
All animal experiments were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986. Forty-five male Sprague-Dawley rats (Charles River, UK) weighing 250-300 g at the start of the study were housed 2-3 rats/cage. Animals were maintained in a standard 12-hour light/dark cycle with free access to food and water.
Stereotaxic injection
Animals were kept under isoflurane anesthesia (5% in 100% O 2 for induction and 2.5% in 100% O 2 for maintenance). The nose bar was set at -3.3 mm. All injections were made using a 20 µl
Hamilton syringe held within an automated syringe pump (World Precision Instruments), and the injection rate was 0.5 µl/min.
6-OHDA lesioning and lentiviral vector injections for vector integration analysis
Thirty minutes prior to surgical procedures, animals were injected with a combined solution of pargyline (5 mg/kg, i.p) and desipramine (25 mg/kg, i.p). A single injection of 6-OHDA (12.5 µg in 2.5 µl of 0.9% saline and 0.02% ascorbic acid) was made into the median forebrain bundle (co-ordinates from Bregma: AP -2.8; ML +2.0; DV -9.0 mm). Animals were then allowed to recover for two weeks. To assess the effectiveness of 6-OHDA lesioning, animals were habituated in 40 cm flat-bottomed hemispherical bowls for 15 min. Animals were then injected with apomorphine hydrochloride (Tocris, UK; 1 mg/kg, i.p, dissolved in sterile water). non-lesioned IDLV (n = 3), non-lesioned IPLV (n = 3), and non-lesioned vehicle (n = 2). One week post-vector injection, animals were killed by exposure to a rising concentration of CO 2 followed by cervical dislocation. The striata were rapidly dissected into RNAlater for subsequent LAM-PCR.
Integration site analyses by 3'LTR-mediated LAM-PCR
3'LTR LAM-PCR was performed as previously described to determine the lentiviral vector integration sites (Schmidt and others 2007) . In brief, 400-1100 ng of DNA per sample was used for linear PCR to pre-amplify 3' vector genome junctions. After double-strand synthesis, restriction digestion (Tsp509I and HpyCH4IV) and adapter ligation, two nested exponential PCRs were performed. LAM-PCR amplicons were prepared for sequencing by 454 technology (454/Roche system) as previously described (Paruzynski and others 2010). A final PCR step was set up to include 454 sequencing adaptors and sample-specific barcodes. After sequencing, the obtained sequences were trimmed and aligned to the rat genome (assembly rn4) by a semiautomated bioinformatical data mining pipeline as previously described (Arens and others 2012).
Lentiviral vector injections and 6-OHDA lesioning to test neuroprotective effects
Animals received a single injection of either IPLV-GFAPp-hGDNF (n = 10), IDLV-GFAPphGDNF (n = 10), IPLV-GFAPp-eGFP (n = 5) or IDLV-GFAPp-eGFP (n = 5) into two sites of the right striatum (5 µl/site; 10 9 viral DNA copies/ml or 2x10 4 ng p24/ml). Stereotaxic co- 
Amphetamine-induced rotational behavior in hGDNF-treated animals
Rotational tests were performed from three weeks after 6-OHDA lesioning, once per month for a period of 4 months. Animals were acclimatized in 40 cm diameter bowls for 30 min prior to injection with amphetamine (Sigma, UK, 5 mg/kg, i.p, dissolved in sterile water). The rotations were assessed for 90 min post-injection as one whole head to tail revolution, with contralateral and ipsilateral rotations counted separately.
GDNF detection by ELISA
Animals were sacrificed by cervical dislocation as described above. The striata were isolated and frozen immediately in liquid nitrogen. Tissues were homogenized in complete lysis buffer (Roche, UK) followed by a centrifugation at 14000 g, 4 o C for 15 min. Levels of GDNF were determined by hGDNF ELISA kit (Promega, UK) following the manufacturer's instructions.
Immunohistochemistry
Rat brains were collected, fixed in ice-cold 4% PFA and maintained at 4 (Cat A21428, 1:500, Invitrogen, UK) antibody for an hour, in the dark. After another three washes in 1X PBS, sections were incubated with 1 µg/ml DAPI for 15 min and subsequently washed in 1X PBS before being mounted onto SuperFrost slides.
Image capture
Brain sections were visualized under an inverted fluorescence Axio Observer D1 microscope.
Images were captured with an AxioCam combined with AxioVision software. Equipment and software were from Carl Zeiss, UK.
Cell counts
Overlapping parts from each section containing the SN were captured and stitched automatically by AxioVision software to create a mosaic image of the section. SNpc-containing serial sections were averaged to obtain the total TH+ cell number per section of the SNpc in the corresponding brain hemisphere.
Measurement of eGFP intensity
After image capture, the area of the striatum on each section was subsequently identified according to the Paxinos and Watson Rat Brain Map (6 th edition, 2007). The eGFP intensity within this area was quantified by AxioVision software and divided by the area to obtain the value of eGFP intensity, expressed as arbitrary units per µm 2 . The values for approximately 60 striatal sections from each brain were averaged to obtain the value for the corresponding brain.
Statistical analysis
Using Prism 5 software (GraphPad, San Diego, California, USA), data were analyzed and shown as means ± S.E.M, with error bars representing the S.E.M. "n" refers to the number of animals per group. Comparisons of statistical significance were assessed by one-or two-way ANOVA followed by Bonferroni's post-hoc test or 2-tailed Student's t-test. Significant levels were set at *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Residual integration levels of IDLVs in intact and lesioned rat striata
We and others have demonstrated that IDLVs only integrate at residual levels in a variety of tissues, including the CNS (Chick and others 2012; Mátrai and others 2011; Yáñez-Muñoz and others 2006). To confirm that this is also the case in the 6-OHDA-lesioned rat brain we performed comparative large-scale lentiviral insertion site analysis by linear amplificationmediated PCR (LAM-PCR) followed by high-throughput sequencing (pyrosequencing).
Animals were lesioned with 6-OHDA or mock-treated, and 18 days later injected in the right striata with IDLV or IPLV expressing eGFP. One week after vector injection, striata were harvested and analyzed for vector integration. As expected, there were considerably fewer integration sites for IDLVs than IPLVs (Table 1) . Most interestingly, frequencies of integration events were broadly similar within vector types when comparing lesioned and non-lesioned striata. These data suggest that disease status had no effect on the overall integration frequency of lentiviral vectors. Supp Table 1 details the integration sites of IDLVs in the present study.
Lentiviral vector-mediated eGFP expression in the striatum of 6-OHDA-lesioned rats
Animals were injected with IPLV-and IDLV-GFAPp-eGFP vectors, followed by 6-OHDA lesioning two weeks later. Brain tissue was harvested 5 months post vector injection. We firstly demonstrated successful transduction with widespread eGFP production within the striatum (Figs. 1a,b) . Cell identification by morphology and marker expression indicated specific cell types were targeted, with mainly astrocytes being transduced; no significant microglia or neuron transduction was noticed (Figs. 1c,d) . Levels of eGFP in groups treated with IDLVs were about 2-fold lower than in those receiving IPLVs (Fig. 1e) . No eGFP expression in the non-injected hemisphere (Fig. 2a) or anterograde expression in the SNpr (Fig. 2b) was detected. Our data suggest a modest, spatially restricted activation of both astrocytes and microglia in the area surrounding the injection site (Figs. 2c,d ).
hGDNF neuroprotection on dopaminergic neurons in the SNpc of 6-OHDA-lesioned rats GDNF is naturally secreted by glial cells (Lin and others 1993), and complications from neuronal transgene expression are possible (Jakobsson and Lundberg 2006) . Following this rationale, we employed an astrocyte-specific promoter, the glial fibrillary acidic protein promoter (GFAPp), to drive lentivector-mediated GDNF expression in our neuroprotection experiments. Animals were injected with IPLV-or IDLV-GFAPp-hGDNF vectors, using eGFPexpressing vectors as controls, followed two weeks later by 6-OHDA lesioning. Levels of hGDNF (measured by ELISA 5 months post-injection) in ipsilateral striata of rats receiving hGDNF vectors were 60 to 250-fold higher than in contralateral striata or in eGFP-treated rats.
We also observed a five-fold difference in hGDNF levels between IPLV-and IDLV-hGDNFtreated groups, higher in the former (Fig. 3) .
We investigated the potential neuroprotective effects of hGDNF on dopaminergic neurons by estimating the loss of TH+ cells in the SNpc five months post vector injection and lesioning.
Following a 10 µg striatal injection of 6-OHDA, a 50% reduction from normal levels of dopaminergic cell bodies was detected in the ipsilateral hemisphere of control (eGFP-treated) groups. The reduction was only 30% in hGDNF-treated animals, with no statistical difference between IPLVs and IDLVs despite the 5-fold difference in hGDNF levels (p =0.48, Fig. 4a ).
Figs. 4b-d show representative images of the SN with no damage in the contralateral hemisphere, 30% TH+ cell loss in the ipsilateral hemisphere of hGDNF-treated groups and 50%
TH+ cell loss in the ipsilateral hemisphere of eGFP-treated groups, respectively. These data indicate an effective neuroprotection by hGDNF on dopaminergic neurons regardless of lentiviral integration proficiency.
Behavioral recovery of hGDNF-treated rats
The vector-injected and 6-OHDA-lesioned animals were subjected to amphetamine-induced rotational tests performed monthly, starting from 3 weeks post-lesioning. Animals showed a normal weight gain with no difference between groups (p = 0.59, Fig. 5a ). A time-dependent reduction in number of rotations was observed in all groups (Fig. 5b) . However, an extensive recovery, with 98% reduction in rotational turns by the third test, was only seen in hGDNFtreated animals, regardless of vector integration-proficiency. In contrast, those injected with eGFP vectors presented only 66% reduction. Furthermore, we detected significant differences in rotational behavior between eGFP-and hGDNF-treated groups within tests, starting from the second test. By quantifying the number of rotations at 10 minute intervals, we noted that these differences occurred from minute 50 onwards (Figs. 6a-d ). These results demonstrate that higher hGDNF expression resulting from IPLV administration (Fig. 3a) does not lead to any significant difference in the behavioral recovery compared to IDLVs (p = 0.36).
Discussion
Since we and others first reported safe and efficient in vivo transduction with IDLVs ( In the current study the astrogliosis was prolonged up to 5 months, the end of the experiment, whereas Drinkut and colleagues reported that activated cells disappeared 3 months post-injection (Drinkut and others 2012). A possible explanation can be that in our study both vectors and 6-OHDA were administered into the same location, with concomitant doubling of physical trauma to the brain regions following repeated injections. As such, our approach may cause more physical damage than vector injection into the brain separated from intraperitoneal injection of MPTP in the previous study.
The neuroprotective effects of GDNF were also confirmed here through an improvement in amphetamine-induced rotational asymmetry of treated animals. Rats with a partial 6-OHDA lesion (less than 70% nigral dopaminergic cell loss) improve their rotational behavior over time, here. However, only those animals injected with hGDNF-expressing vectors displayed an essentially complete recovery of behavior, which started from week 9 following vector injection.
This recovery occurred regardless of vector integration proficiency.
In the present study, we chose to test a neuroprotection approach in which hGDNF lentivectors were administered prior to 6-OHDA lesioning. This strategy should be optimal for prevention of axonal retraction and subsequent neuronal death and indeed rendered a positive outcome.
However, in PD patients the effects of neurotrophic factor therapy may also include neurorestoration of damaged neurons and neuroregeneration with new neurons in the injured regions. Therefore, further assessment of the effectiveness of IDLV-hGDNF expression for PD should include an experimental strategy in which 6-OHDA lesioning precedes the injection of therapeutic vector.
In summary, our study demonstrates IDLV-mediated neuroprotection in rats when intrastriatal hGDNF expression precedes 6-OHDA-lesioning. These data also show promoter-mediated celltype specificity from IDLVs, with a focus on effective astrocytic transgene expression. We demonstrate both efficient delivery and long-lasting expression of a therapeutically relevant transgene by IDLVs at low dose. We also demonstrate lack of significant IDLV integration in this PD lesion model, supporting these safer vectors as potential tools in gene therapy for PD treatment, and by extension for other major diseases of the CNS. Our data warrant further exploration of IDLVs in PD-relevant models, in particular non-human primates, prior to considering clinical application. Demonstration of safety and efficacy in such models would strongly support the use of IDLVs in first-in-man studies. hGDNF-treated groups showed a significantly improved recovery of behavior starting from the 2 nd monthly test, with similar improvements regardless of vector integration proficiency. Data were analyzed for statistical significance by two-way ANOVA and Bonferroni's post-hoc test.
Error bars represent the S.E.M; n = 10 per group; *p<0.05. The following groups of animals were analyzed: lesioned IDLV (n = 5), lesioned IPLV (n = 4), non-lesioned IDLV (n = 3), non-lesioned IPLV (n = 3). LAM-PCR samples were subjected to high-throughput pyrosequencing. The raw sequence data were processed to determine possible integration sites. These were mapped onto the rat genome, with the majority being exactly mappable and few multiple hits. A total of 104601 sequence reads were obtained, distributed as follows: lesioned IDLV (38917), lesioned IPLV (38162), nonlesioned IDLV (15080), non-lesioned IPLV (12442).
